We have been privileged to conduct studies of our PLX cells in collaboration with renowned researchers at internationally recognized institutions. Many of the clinical and preclinical studies of our PLX-PAD cells were conducted in collaboration with leading academics at important centers including the Beth Israel Deaconess Medical Center and Texas A&M University in the U.S., the Charité University Hospital and the Berlin-Brandenburg Center for Regenerative Therapies in Germany, and Hadassah Medical Center in Israel. In October, 2015, we expanded a five-year Collaborative Research Agreement with the Berlin-Brandenburg Center for Regenerative Therapy to include identification of orthopedic indications that may be eligible for development under Europe’s Adaptive Pathways project.
We developed PLX-R18, our second product, in conjunction with Charité Universitätsmedizin Berlin Institute of Medical Immunology, the Berlin-Brandenburg Center for Regenerative Therapies, Hadassah Hebrew University Medical Center, and Indiana University; the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), provided support for the research conducted at Indiana University. We also have a memorandum of understanding with Fukushima Medical University, Fukushima Global Medical Science Center, in Fukushima, Japan, to collaborate on the development of PLX-R18 cells for the treatment of Acute Radiation Syndrome (ARS), and as an adjunct to radiotherapy in cancer patients.